In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.
News|Articles|September 17, 2026
Q&A: What the First FDA-Approved PDT for Skin Cancer Means for sBCC Care
Author(s)Neal Bhatia, MD
Fact checked by: Tim Smith
Neal Bhatia, MD, weighs the newly approved Ameluz PDT regimen for sBCC against Mohs surgery, citing its 66% composite response rate.
Advertisement
Advertisement
Biofrontera's Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, paired with the BF-RhodoLED lamp series, has received an approval by the
Related to this article
In this Q&A, Leon Kircik, MD, discusses challenging watch-and-wait for molluscum contagiosum with berdazimer gel, 10.3%, at LEADderm 2026.
In this feature, several leaders in the dermatology space were asked how far we have come and where the field is headed in precision medicine.
FDA accepts Cogent's bezuclastinib NDA for advanced systemic mastocytosis, backed by APEX trial data showing durable, high-rate responses.
New research links wildfire smoke to lasting respiratory decline and skin flares, months after exposure ends.
Ameluz is now the first FDA-approved photodynamic therapy for a skin cancer, expanding use to superficial basal cell carcinoma (sBCC) in adults.
Adam Friedman, MD, breaks down how to say no strategically in dermatology, from delaying an answer to sharing the decision with the requester.
Kristina Duffin, MD, dean of the Spencer Fox Eccles School of Medicine, discusses leadership, delegation, and coaching at LEADderm 2026.
Advertisement
Advertisement